Regulatory roundup: BioMarin poised to have first U.S., EU hemophilia gene therapy; plus Allergan, Eisai, FibroGen, ViiV and Vero

Monday's basket of regulatory news includes two landmark regulatory applications for BioMarin's hemophilia gene therapy in the U.S. and EU, and FDA approval of Allergan's migraine drug.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) submitted a BLA to FDA for valoctocogene roxaparvovec for hemophilia A and announced EMA accepted an MAA for the adeno-associated virus subtype 5 (AAV5) vector delivering Factor VIII to treat

Read the full 614 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE